Neuroprotekció parkinson-kórban és egyéb neurodegeneratív betegségekben: Kísérletes és kllnikai adatok

Translated title of the contribution: Neuroprotection in parkinson's disease and other neurodegenerative disorders: Preclinical and clinical findings

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The authors summarized the evidence supporting neuroprotection based on the data available in the literature. In vivo and in vitro studies have indicated that many compounds can decrease neurodegeneration, excitotoxicity, oxidative stress, protein aggregation, disturbance of Ca2+ homeostasis and compensate the energy impairment. Selegiline, rasagiline, dopamine agonists and other molecules (ubiquinone, kynurenic acid, tocopherol, creatine, glatiramer acetate) exert neuroprotective effects in preclinical studies. Much less clinical data are available regarding neuroprotection in different neurological disorders. In this review, such preclinical and clinical evidences are summarized.

Translated title of the contributionNeuroprotection in parkinson's disease and other neurodegenerative disorders: Preclinical and clinical findings
Original languageHungarian
Pages (from-to)25-34
Number of pages10
JournalIdeggyogyaszati szemle
Volume62
Issue number1-2
Publication statusPublished - Jan 30 2009

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Neuroprotection in parkinson's disease and other neurodegenerative disorders: Preclinical and clinical findings'. Together they form a unique fingerprint.

  • Cite this